Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

$96m RNA Research and Manufacturing Facility opens in NSW

The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...

Cartherics and Catalent announce enhanced partnership

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Alliance seeks to boost regional capacity in clinical trials

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Content from other channels on our network

A palliative care nurse on why good intentions aren't enough

National Palliative Care Week 2026 commences

As AI reshapes health care, human skills are more important than ever

Optometry Australia to unify into single national entity

NSW announces review into 'stranded' aged care patients

Bringing a board game to life with CODESYS

Titomic to redomicile to the United States

Mars invests $200m to boost its local manufacturing capacity

Overpressure protection in critical systems: the role of rupture discs in preventing costly downtime

Critical minerals facility opens in Sydney

Green schemes take a hit in federal Budget 2026

Solar rebate saves $75K for Vic apartment residents

70% of Aussies can recycle soft plastics again

Food waste creates premium shiraz

University uses AI to accelerate solar panel recycling